Neuromodulation

Between January 1 and June 1, 2026, seven MedTech-related mini-HTAs were initiated in Norway across orthopedics, neurology and rehabilitation, in vitro diagnostics, interventional radiology, diagnostic imaging, and e-health. These assessments are conducted as part of Norway’s framework for the managed introduction of innovations, known as “New Methods”.

In April 2026, the Canary Islands Healthcare Evaluation Service is working on several HTAs, including evaluations in e-health, IVD, neuromodulation, obstetrics and gynecology, and some other fields.

On January 30, 2026, the Institute for the Hospital Remuneration System (InEK) published the list of innovation funding (NUB) requests submitted by hospitals in 2025. The medical technologies of cardiovascular, endoscopy, extracorporeal, gastrointestinal, neuromodulation, peripheral vascular, and other technology groups obtained a positive status 1.

The French National Authority for Health (HAS) released new recommendations on the registration of medical devices and medical aids in the List of Reimbursable Products and Services (LPPR) following the December 2025 meetings of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS). Four favourable opinions were issued concerning add-on reimbursement for medical devices in the ENT, neuromodulation, and peripheral vascular fields.

On November 28, 2025, the entity managing the DRG system in Switzerland, SwissDRG, published the final (billing) version of the 2026 DRG system. In total, 19 new DRGs related to cardiovascular, ENT, gastrointestinal, neurology and neurosurgery, obstetrics and gynecology, orthopedics, and some other fields were introduced. Also, four new add-on reimbursement categories were added.

In June-July 2025, Health Technology Wales (HTW) accomplished one full appraisal on implantable tibial neuromodulation devices for urinary incontinence. In addition, seven Med Tech-related Topic Exploration Reports were published in the e-health, diagnostic imaging, in-vitro diagnostics, neurology, and radiotherapy fields.

As of August 2025, the Centre for Assessment of Medical Technology in Örebro region in Sweden is working on health technology assessments in several areas, including in-vitro diagnostics, neuromodulation, and orthopedics.

As of August 2025, the Scottish Health Technology Group is developing four Med Tech-related HTAs in cardiovascular, diagnostic imaging, neurology and neurosurgery, neuromodulation, and orthopedics areas.

In June 2025, Belgian INAMI/RIZIV updated the List of implants and invasive medical devices. Four new reimbursement codes were added to the List in relation to heart valve replacement. Several Nominative lists of brands were updated as well in the fields of neuromodulation, neurovascular, orthopedic, and cardiovascular.

In May 2025, the National Institute for Health and Care Excellence (NICE) published two new Early Value Assessments (Digital therapy for chronic tic disorders and Tourette syndrome, AI technologies for skin lesions) and one new Late Stage Assessment (Drug-eluting stents for coronary artery disease). Furthermore, three clinical guidelines were updated.

In May 2025, the evaluation phase of the “New Methods” framework was completed for three technologies: leadless pacemaker for cardiac arrhythmias, MR-guided focused ultrasound for essential tremor, and Electrical Field Therapy for glioblastoma treatment. As the recommendations from HTA are now available, the Decision Forum needs to make coverage decisions for these technologies.

The French National Authority for Health (HAS) released new recommendations regarding the registration of medical devices and medical aids in the List of Reimbursable Products and Services (LPPR) following the April 2025 meetings of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS). Eleven favorable opinions were published concerning the registration of new devices or modifying conditions/indications for existing ones in the LPPR List. The recommendations relate to devices in the fields of endocrine, e-health, neuromodulation, peripheral vascular, and medical aids.